Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Mayne Pharma (MYX AU)
Watchlist
225
Analysis
Health Care
•
Australia
Mayne Pharma Group Ltd. develops and manufactures oral pharmaceuticals. The Company produces branded generics, specialty generics, and active pharmaceutical ingredients.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Johns Lyng
•
13 Jul 2025 06:15
(Mostly) Asia-Pac M&A: Johns Lyng, New World Resources, Oneconnect, Great Eastern, VIOL
This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...
David Blennerhassett
Follow
461 Views
Share
bearish
•
Seven & I Holdings
•
07 Jul 2025 01:21
Merger Arb Mondays (07 Jul) - Seven & I, Shibaura, Insignia, New World, ENN Energy, HKBN, Fengxiang
I summarise the latest spreads and newsflow of merger arb situations we cover across Hong Kong, Australia, New Zealand, Singapore, Japan,...
Arun George
Follow
1k Views
Share
bullish
•
Nissin Corp
•
06 Jul 2025 06:15
(Mostly) Asia-Pac M&A: Talkmed, Jilin Jiutai Bank, Insignia, Silk Logistics, Fengxiang, Nissin, VIOL
This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...
David Blennerhassett
Follow
637 Views
Share
bullish
•
Santos Ltd
•
01 Jul 2025 06:15
(Mostly) Asia M&A, June 2025 Wrap: Santos, Fuji Corp, Brickworks, Great Eastern, VIOL, Adriatic
For the month of June, 11 new deals were discussed on Smartkarma with an overall deal size of just ~US$29bn. The average premium for the new deals...
David Blennerhassett
Follow
469 Views
Share
bullish
•
TalkMed Group
•
30 Jun 2025 11:24
TalkMed (TKMED SP)'s Super Clean Scheme
Super clean deal - 82.99% of the register are supportive. Trading tight at 1.3%/8.4% gross/annualised. If illiquid arbs are your bag, and not in,...
David Blennerhassett
Follow
390 Views
Share
First
Previous
17
18
19
20
21
22
23
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x